Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus IRBESARTAN AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus IRBESARTAN AND HYDROCHLOROTHIAZIDE.
AVALIDE vs IRBESARTAN AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Irbesartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to AT1 receptors, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
Oral: 1 tablet (irbesartan 150 mg / hydrochlorothiazide 12.5 mg or irbesartan 300 mg / hydrochlorothiazide 12.5 mg or irbesartan 300 mg / hydrochlorothiazide 25 mg) once daily, with or without food. Maximum: irbesartan 300 mg/hydrochlorothiazide 25 mg daily.
None Documented
None Documented
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Irbesartan: 11-15 hours; Hydrochlorothiazide: 6-15 hours. Steady state achieved in 3-5 days.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Irbesartan: primarily biliary (80%) and renal (20%); Hydrochlorothiazide: renal (≥95% as unchanged drug).
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB